From genes to drugs: targeting Alzheimer’s with circadian insights

TL;DR

This study identifies clock genes linked to Alzheimer's disease and suggests potential biomarkers and drugs for treatment.

Contribution

The paper introduces three clock gene biomarkers for Alzheimer's and identifies drugs targeting them.

Findings

Nine differentially expressed clock genes were identified between Alzheimer's and control groups.

Three genes (ERC2, PRKCG, HLA-DMA) were validated as potential diagnostic biomarkers for Alzheimer's.

23 drugs targeting HLA-DMA and 8 drugs targeting PRKCG were identified as potential therapies.

Abstract

Alzheimer’s disease (AD) is a typical neurodegenerative disease that presents challenges due to the lack of biomarkers to identify AD. A growing body of evidence highlights the critical role of circadian rhythms in AD.

The differentially expressed clock genes (DECGs) were identified between AD and ND groups (non-demented controls). Functional enrichment analysis was executed on the DECGs. Candidate diagnostic biomarkers for AD were screened by machine learning. ROC and nomograms were constructed to evaluate candidate biomarkers. In addition, therapeutics targeting predictive biomarkers were screened through the DGIdb website. Finally, the mRNA–miRNA network was constructed.

Nine genes were identified through the DECG analysis between the AD and ND groups. Enrichment analysis of nine genes indicated that the pathways were enriched in long-term potentiation and circadian entrainment. Four clock genes (GSTM3, ERC2, PRKCG, and HLA-DMA) of AD were screened using Lasso regression, random forest, SVM, and GMM. The diagnostic performance of four genes was evaluated by the ROC curve. Furthermore, the nomogram indicated that ERC2, PRKCG, and HLA-DMA are good biomarkers in diagnosing AD. Single-gene GSEA indicated that the main enrichment pathways were oxidative phosphorylation, pathways of neurodegeneration-multiple diseases, etc. The results of immune cell infiltration analysis indicated that there were significant differences in 15 immune cell subsets between AD and ND groups. Moreover, 23 drugs targeting HLA-DMA and 8 drugs targeting PRKCG were identified through the DGIdb website.

We identified three predictive biomarkers for AD associated with clock genes, thus providing promising therapeutic targets for AD.

Figures